We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Mitochondrial Biomarker Predicts Type 2 Diabetes Risk

By LabMedica International staff writers
Posted on 02 Aug 2022

Type 2 diabetes (T2D) is characterized by chronic hyperglycemia primarily caused by both impaired insulin secretion by pancreatic β-cells (insulinopenia) and defective insulin signaling in metabolically active tissues (insulin resistance). More...

The nuclear-encoded protein ATPase inhibitory factor 1 (IF1) is an endogenous inhibitor of the mitochondrial ATP synthase. For a long time, IF1 was thought to act only as an inhibitor of the reverse ATPase activity of the ATP synthase. However, recent data indicate that IF1 also partially inhibits the synthetic activity of the ATP synthase in mitochondria, thus limiting oxidative phosphorylation (OXPHOS).

Molecular Biochemists at the Université de Toulouse (Toulouse, France) and their colleagues conducted a prospective study, where the baseline plasma level of IF1 was measured in 307 participants with prediabetes. The primary outcome was the incidence of new onset diabetes (NOD) within five years of follow-up. Cross-sectional analysis of the IF1 level was also done in two independent interventional studies. Correlations between plasma IF1 and metabolic parameters at baseline were assessed by Spearman’s correlation coefficients, and the association with the risk of NOD was determined using Cox proportional‐hazards models.

Biological analyses including plasma triglycerides (TG), total cholesterol, HDL-cholesterol (HDL-C), glucose, glycated hemoglobin (HbA1c), aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (g-GT), insulin and high-molecular-weight adiponectin (HMW-adiponectin) were performed. Plasma apoA-I and IF1 were measured by a liquid chromatography–tandem mass spectrometry (LC-MS/MS) method. Analyses were performed on a Xevo TQD mass spectrometer with an electrospray interface and an Acquity H-Class UPLC device (Waters, Milford, MA, USA).

The scientists reported that the mean IF1 plasma level was lower in participants who developed NOD than in those who did not (537 ± 248 versus 621 ± 313 ng/mL). The plasma IF1 level negatively correlated with clinical variables associated with obesity and insulin resistance, including the BMI and HOMA-IR. Conversely, IF1 was positively associated with plasma markers of cardiometabolic health, such as HDL-C and apoA-I. These correlations were confirmed in cross-sectional analyses. In Therapeutic Innovation in Type 2 DIABetes (IT-DIAB) cohort, the IF1 level was significantly associated with a lower risk of T2D after adjustment for age, sex, and fasting plasma glucose (HR [95% CI] per 1 SD = 0.76 [0.62; 0.94].

The authors concluded that they had identified plasma IF1 as a determinant of T2D onset in high-risk populations, independently of age, sex, and fasting plasma glucose levels. IF1 measurements are foreseen within the framework of other prospective cohorts of individuals at different risks of T2D to more firmly establish the predictive value of IF1 measurements in the assessment of T2D risk along with established risk factors. The study was published on July 26, 2022 in the journal Research Square.

Related Links:
Université de Toulouse 
Waters 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.